Search Results - "Sonoda, Norikazu"
-
1
Clinicopathological Analysis of Early-Stage Gastric Cancers Detected After Successful Eradication of Helicobacter pylori
Published in Helicobacter (Cambridge, Mass.) (01-06-2011)“…Background and Aims: The results of a randomized controlled study and meta‐analysis study have recently proved that Helicobacter pylori eradication has a…”
Get full text
Journal Article -
2
Observational Cohort Study of 1St Line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer: Hgcsg0802
Published in Annals of oncology (01-10-2014)Get full text
Journal Article -
3
Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802—Analysis of early tumor shrinkage (ETS)
Published in Journal of clinical oncology (01-02-2016)“…Abstract only 753 Background: It was reported that early tumor shrinkage (ETS) was associated with better overall survival (OS) in patients (pts) with…”
Get full text
Journal Article -
4
Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901
Published in Journal of clinical oncology (20-01-2015)“…Abstract only 781 Background: The GERCOR index (GI) based on performance status and serum LDH was reported to be useful to predict survival for patients with…”
Get full text
Journal Article -
5
Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802
Published in Journal of clinical oncology (20-01-2015)“…Abstract only 749 Background: It was reported that early tumor shrinkage (ETS) was associated with better overall survival (OS) in patients (pts) with…”
Get full text
Journal Article -
6
The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies
Published in Journal of clinical oncology (20-05-2013)“…Abstract only e14604 Background: The safety and efficacy of first-line IRIS (S-1 in combination with irinotecan; Komatsu Y, et al. Oncology, 2011) and IRIS/Bev…”
Get full text
Journal Article -
7
-
8